Gland Pharma Ltd

AI
Gland Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Gland Pharma Ltd

₹ 3,308 1.44%
12 Nov 2:20 p.m.
glandpharma.com BSE: 543245 NSE: GLAND
About

Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.

Key Points

Product Portfolio:[1]
The company is one of the largest and fastest-growing injectable-focused companies, which provides 89+ product SKUs, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions, across 15+ therapeutic areas.[2]

Website BSE NSE
  • Market Cap ₹ 54,579 Cr.
  • Current Price ₹ 3,308
  • High / Low ₹ 3,374 / 1,574
  • Stock P/E 35.6
  • Book Value ₹ 686
  • Dividend Yield 0.60 %
  • ROCE 17.4 %
  • ROE 12.8 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 28.0%

Cons

  • Promoter holding has decreased over last quarter: -6.02%
  • The company has delivered a poor sales growth of 5.62% over past five years.
  • Company has a low return on equity of 12.3% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 Nifty Pharma Nifty MNC

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
1,011 1,098 1,175 1,012 1,063 1,011 1,030 1,039 1,074 1,178 1,262 1,287 1,402
664 728 742 718 699 620 636 680 699 756 754 813 854
Operating Profit 347 369 433 294 364 391 394 359 375 422 508 474 548
OPM % 34% 34% 37% 29% 34% 39% 38% 35% 35% 36% 40% 37% 39%
41 43 47 48 58 65 44 55 83 36 106 59 71
Interest 1 1 5 1 0 18 3 7 4 0 6 1 3
Depreciation 40 40 43 41 42 44 43 44 45 45 43 44 45
Profit before tax 347 372 433 300 380 394 391 362 409 412 565 488 571
Tax % 26% 26% 26% 26% 26% 25% 26% 26% 26% 25% 26% 25% 26%
258 277 321 223 282 295 290 269 302 308 420 364 425
EPS in Rs 15.64 16.81 19.51 13.53 17.10 17.91 17.60 16.34 18.33 18.69 25.52 22.09 25.75
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
994 1,348 1,479 1,620 2,044 2,633 3,463 4,401 3,617 4,167 4,116 4,552 5,128
678 845 854 1,085 1,338 1,678 2,161 2,890 2,598 2,758 2,674 2,889 3,177
Operating Profit 316 502 625 535 706 955 1,302 1,511 1,019 1,410 1,443 1,663 1,951
OPM % 32% 37% 42% 33% 35% 36% 38% 34% 28% 34% 35% 37% 38%
30 37 34 49 66 139 135 224 184 166 215 279 272
Interest 17 16 6 4 4 7 3 5 7 8 23 18 11
Depreciation 57 63 74 78 82 95 99 110 147 162 169 176 177
Profit before tax 272 459 578 502 686 993 1,335 1,619 1,048 1,405 1,466 1,748 2,036
Tax % 23% 32% 28% 36% 34% 22% 25% 25% 26% 26% 26% 26%
209 314 414 321 452 773 997 1,212 776 1,043 1,090 1,300 1,518
EPS in Rs 13.35 20.25 26.71 20.73 29.17 49.88 60.94 73.78 47.11 63.34 66.14 78.88 92.05
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 32% 27% 25%
Compounded Sales Growth
10 Years: 13%
5 Years: 6%
3 Years: 8%
TTM: 23%
Compounded Profit Growth
10 Years: 15%
5 Years: 6%
3 Years: 17%
TTM: 33%
Stock Price CAGR
10 Years: %
5 Years: -1%
3 Years: 26%
1 Year: 78%
Return on Equity
10 Years: 15%
5 Years: 13%
3 Years: 12%
Last Year: 13%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 16 15 16 16 16 16 16 16 16 16 16 16 16
Reserves 1,379 1,662 2,074 2,395 2,847 3,631 5,887 7,142 7,937 8,979 9,739 10,794 11,304
166 117 6 6 5 5 5 5 4 4 5 3 3
197 292 378 512 655 435 588 671 815 542 661 794 904
Total Liabilities 1,758 2,086 2,474 2,928 3,523 4,086 6,496 7,834 8,773 9,541 10,422 11,607 12,228
649 788 872 843 929 968 954 1,502 1,571 1,694 1,745 1,688 1,651
CWIP 192 202 161 199 123 188 338 191 177 120 42 138 191
Investments 0 0 0 0 0 0 1 163 8 2,386 2,790 3,293 3,293
917 1,096 1,441 1,887 2,471 2,929 5,203 5,978 7,017 5,342 5,845 6,489 7,093
Total Assets 1,758 2,086 2,474 2,928 3,523 4,086 6,496 7,834 8,773 9,541 10,422 11,607 12,228

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
220 476 202 185 701 605 791 368 1,136 1,074 1,135
-12 -100 -359 -319 -761 -1,521 -1,007 1,211 -2,918 1,582 -74
-93 -116 -4 -3 -7 1,238 35 15 -7 -340 -316
Net Cash Flow 115 260 -160 -136 -67 322 -181 1,594 -1,789 2,316 745
Free Cash Flow 33 360 117 50 530 377 270 145 899 962 917
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 67% 102% 67% 58% 99% 70% 79% 67% 103% 99% 93%

Ratios

Standalone / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 62 95 103 107 90 83 71 89 87 103 101 122
Inventory Days 283 248 271 283 388 250 312 205 421 253 265 257
Days Payable 58 60 136 161 190 82 97 80 128 56 81 99
Cash Conversion Cycle 288 283 239 229 289 251 286 214 381 299 284 280
Working Capital Days 141 155 154 185 191 161 169 168 241 224 249 209
ROCE % 22% 28% 30% 22% 27% 30% 28% 25% 15% 17% 16% 17%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
R&D Expenses as % of Revenue
%

Log in to view insights

Please log in to see hidden values.

Login
Cumulative ANDA Approvals (US)
count
Cumulative ANDA Filings (US)
count
US as % of Group Revenue
%
US Market Revenue (Consolidated)
INR Mn
Cenexi Revenue (European CDMO Subsidiary)
EUR Mn
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

18 Recently
Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
57.86% 57.86% 51.83% 51.83% 51.83% 51.83% 51.83% 51.83% 51.83% 51.83% 51.77% 45.75%
4.05% 3.59% 6.88% 4.48% 5.04% 6.90% 7.39% 7.90% 7.58% 7.29% 8.74% 10.36%
24.17% 25.23% 32.83% 35.37% 34.80% 33.27% 32.86% 32.63% 32.99% 33.36% 30.44% 33.21%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01%
13.93% 13.32% 8.46% 8.33% 8.33% 8.00% 7.93% 7.63% 7.62% 7.52% 9.06% 10.68%
No. of Shareholders 1,36,0211,22,3751,22,6651,22,3581,21,0751,13,7881,10,67197,15194,57891,5001,08,2661,25,667

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls